← Leaderboards
Larry Zeitlin
Epicyte Pharmaceutical, Inc.
$59,655,519
Attributed
$60,152,195
Total exposure
23
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$60,152,195 · 23
By mechanism
U01$16,041,833 · 2
U19$15,474,323 · 4
R44$11,994,717 · 5
R01$11,533,974 · 2
R43$3,526,966 · 8
SB1$993,353 · 1
Top collaborators
- Ellen Monson1 shared
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesMonoclonal AntibodiesIn VivoLeadProductionSafetyPreventPharmaceutical PreparationsPharmacology And ToxicologyInfectionIn VitroCostDosePreventionCategoriesBaseBiological ProductsVirusBiological WarfareNonhuman PrimateCommunicable DiseasesNicotianaPlantsProduct Development
Grant awards (65)
Development of highly potent human monoclonal for RSV immunoprophylaxis$993,353
SB1 · FY2025 · AI
Core D: Early and IND-Enabling Translational Research for Vaccines and MAbs$4,640,499
U19 · FY2024 · AI · contact PI
Core B - MappBiopharmaceutical, Inc.$642,874
U19 · FY2023 · AI · contact PI
Development of highly potent human monoclonal for RSV immuno-prophylaxis$947,868
R44 · FY2022 · AI · contact PI
Core B - MappBiopharmaceutical, Inc.$802,302
U19 · FY2022 · AI · contact PI
Core B - MappBiopharmaceutical, Inc.$1,119,154
U19 · FY2021 · AI · contact PI
Development of highly potent human monoclonal for RSV immuno-prophylaxis$801,020
R44 · FY2021 · AI · contact PI
Development of highly potent human monoclonal for RSV immuno-prophylaxis$998,825
R44 · FY2020 · AI · contact PI
Core B - MappBiopharmaceutical, Inc.$800,065
U19 · FY2020 · AI · contact PI
Core B - MappBiopharmaceutical, Inc.$753,083
U19 · FY2019 · AI · contact PI
Development of highly potent human monoclonals for RSV immunoprophylaxis$300,000
R43 · FY2019 · AI · contact PI
An Immunoprotectant for Argentine Hemorrhagic Fever$1,022,916
R01 · FY2018 · AI · contact PI
Industrialization Core: Production of monoclonal antibodies and product developm$591,012
U19 · FY2018 · AI · contact PI
Development of highly potent human monoclonals for RSV immunoprophylaxis$300,000
R43 · FY2018 · AI · contact PI
Post-exposure immunotherapy for ricin exposure$298,015
R44 · FY2018 · AI · contact PI
An Immunoprotectant for Argentine Hemorrhagic Fever$1,029,383
R01 · FY2017 · AI · contact PI
Industrialization Core: Production of monoclonal antibodies and product developm$683,095
U19 · FY2017 · AI · contact PI
Industrialization Core: Production of monoclonal antibodies and product developm$1,431,733
U19 · FY2016 · AI · contact PI
An Antibody Immunoprotectant for Category B Toxins$1,195,183
R01 · FY2016 · AI · contact PI
An Immunoprotectant for Argentine Hemorrhagic Fever$1,058,986
R01 · FY2016 · AI · contact PI
An Immunoprotectant for Marburg Virus$999,998
R44 · FY2016 · AI · contact PI
Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis$240,221
R43 · FY2016 · AI · contact PI
Industrialization Core: Production of monoclonal antibodies and product developm$1,357,509
U19 · FY2015 · AI · contact PI
An Antibody Immunoprotectant for Category B Toxins$1,265,619
R01 · FY2015 · AI · contact PI
An Immunoprotectant for Argentine Hemorrhagic Fever$1,062,202
R01 · FY2015 · AI · contact PI
An Immunoprotectant for Marburg Virus$999,998
R44 · FY2015 · AI · contact PI
A human monoclonal for RSV prophylaxis$300,000
R43 · FY2015 · AI · contact PI
An Antibody Immunoprotectant for Category B Toxins$1,297,816
R01 · FY2014 · AI · contact PI
An Immunoprotectant for Argentine Hemorrhagic Fever$1,204,507
R01 · FY2014 · AI · contact PI
Industrialization Core: Production of monoclonal antibodies and product developm$1,193,970
U19 · FY2014 · AI · contact PI
An Immunoprotectant for Marburg Virus$999,998
R44 · FY2014 · AI · contact PI
A human monoclonal for RSV prophylaxis$300,000
R43 · FY2014 · AI · contact PI
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)$3,530,196
U01 · FY2013 · AI · contact PI
An Antibody Immunoprotectant for Category B Toxins$1,225,116
R01 · FY2013 · AI · contact PI
A Monoclonal Antibody Immunoprotectant for Ebola Virus$980,000
R44 · FY2013 · AI · contact PI
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)$3,111,286
U01 · FY2012 · AI · contact PI
An Antibody Immunoprotectant for Category B Toxins$1,172,246
R01 · FY2012 · AI · contact PI
A Monoclonal Antibody Immunoprotectant for Ebola Virus$980,000
R44 · FY2012 · AI · contact PI
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)$1,174,260
U01 · FY2011 · AI · contact PI
A Monoclonal Antibody Immunoprotectant for Ebola Virus$1,000,000
R44 · FY2011 · AI · contact PI
Development of a monoclonal immunoprotectant for ricin$300,000
R43 · FY2011 · AI · contact PI
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)$1,151,953
U01 · FY2010 · AI · contact PI
Development of a monoclonal immunoprotectant for ricin$300,000
R43 · FY2010 · AI · contact PI
An Immunoprotectant for Marburg Virus$265,356
R43 · FY2010 · AI · contact PI
Monoclonal Antibodies in Biodefense: Ebola Viruses$1,610,165
U01 · FY2009 · AI · contact PI
Development of a C. difficile Monoclonal-based Product$1,000,000
R44 · FY2009 · AI · contact PI
Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)$991,375
U01 · FY2009 · AI · contact PI
An Immunoprotectant for Marburg Virus$259,520
R43 · FY2009 · AI · contact PI
Monoclonal Antibodies in Biodefense: Ebola Viruses$1,111,806
U01 · FY2008 · AI · contact PI
Development of a C. difficile Monoclonal-based Product$991,988
R44 · FY2008 · AI · contact PI
A Monoclonal Antibody Immunoprotectant for Ebola Virus$268,434
R43 · FY2008 · AI · contact PI
Antibody Based Immunity:HuMabs Against Viral STIs$253,765
U19 · FY2008 · AI · contact PI
Monoclonal Antibodies in Biodefense: Ebola Viruses$1,238,148
U01 · FY2007 · AI · contact PI
Development of a C. difficile Monoclonal-based Product$997,007
R44 · FY2007 · AI · contact PI
A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY$301,705
R41 · FY2007 · AI · contact PI
Antibody Based Immunity:HuMabs Against Viral STIs$285,856
U19 · FY2007 · AI · contact PI
A Monoclonal Antibody Immunoprotectant for Ebola Virus$270,810
R43 · FY2007 · AI · contact PI
Monoclonal Antibodies in Biodefense: Ebola Viruses$1,067,924
U01 · FY2006 · AI · contact PI
Antibody Based Immunity:HuMabs Against Viral STIs$306,592
U19 · FY2006 · AI · contact PI
A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY$285,324
R41 · FY2006 · AI · contact PI
Monoclonal Antibodies in Biodefense: Ebola Viruses$1,054,720
U01 · FY2005 · AI
Antibody Based Immunity:HuMabs Against Viral STIs$304,193
U19 · FY2005 · AI
Antibody Based Immunity:HuMabs Against Viral STIs$308,621
U19 · FY2004 · AI
ANTI-C. DIFFICILE HUMAN MONOCLONALS FOR IMMUNOTHERAPY$300,000
R43 · FY2004 · AI
ANTIBODY FORMULATIONS FOR VAGINAL MICROBICIDES$122,625
R43 · FY2002 · AI